Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.61 percent. This is a 34.69 percent increase over losses of $(0.49) per share from the same period last year. The company reported $3.337 thousand in sales this quarter. This is a 98.38 percent decrease over sales of $205.817 thousand the same period last year.